The tumor necrosis factor inhibitor certolizumab pegol (CZP) is thought to be safe for use during pregnancy.

This biologic agent lacks the antibody Fc- region responsible for placental transfer of immunoglobulins.A recent analysis of the manufacturer’s pharmacovigilance database, representing the largest available cohort of exposed pregnant women (including over 300 women with rheumatic diseases and nearly 200 with Crohn disease), identified over 530 prospectively documented outcomes of maternal exposure. Over 80 percent…